Tacrolimus has been shown to be a powerful suppressor of the immune system. It was introduced into clinical use to prevent allograft rejection and is now routinely used in kidney, liver, and heart transplantation. Recently, 2 double-blind multicenter studies demonstrated the therapeutic efficacy of topical and systemic tacrolimus in the inflammatory skin diseases atopic dermatitis and psoriasis.
MEDLINE was searched for relevant publications and combined with our own clinical, in vitro, and in vivo studies.
All studies dealing with tacrolimus and dermatology were reviewed.
Publications with clinically relevant data were included in this review.
Topical tacrolimus is a safe and effective therapeutic agent that may open a new era in the treatment of inflammatory skin diseases, particularly for patients with atopic dermatitis. Before its full potential in dermatology can be assessed, more clinical experience in treating children and comparison with the criterion standard of anti-inflammatory therapy, glucocorticosteroids, are needed.
Ruzicka T, Assmann T, Homey B. Tacrolimus: The Drug for the Turn of the Millennium? Arch Dermatol. 1999;135(5):574–580. doi:10.1001/archderm.135.5.574
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: